Pharmaceutical company Esperion Therapeutics' stock downgraded to 'hold' by multiple brokerages.
Pharmaceutical company Esperion Therapeutics has seen its stock downgraded by multiple brokerages, including StockNews.com and Bank of America, with the average rating now at 'hold'. The company focuses on developing treatments for high cholesterol and has a consensus target price of $8.17. Its stock, ESPR, opened at $1.96 with a market cap of $371.34 million. Institutional investors hold 47.39% of the company's stock.
August 17, 2024
3 Articles